Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2026 revenue A$261.7m (+22.9%); underlying EBIT margin 74.9%; net income A$265.3m.
Statutory NPAT A$265.3m includes investment gain; underlying NPAT A$144.7m (+24.1%).
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Not yet researched.
Data breaches, cyber incidents, regulator action and assurance status.
Not yet researched.
Recalls, safety notices, regulator action and clinical safety concerns.
Not yet researched.
Contract delivery, go-lives, terminations and disputes.
Not yet researched.